ISOLF: AI 评分 43/100 — AI 分析 (4月 2026)

Isodiol International Inc. develops, markets, and distributes hemp-based consumer packaged goods and solutions in Canada and the United States. The company focuses on phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Isodiol International Inc. operates in the hemp-based consumer packaged goods sector, focusing on developing and marketing phytoceutical products in Canada and the United States. The company utilizes pharmaceutical-grade cannabinoid crystalline isolates and advanced technologies like micro-encapsulation, serving both consumable and topical skincare markets, but faces challenges common to OTC-listed companies.

ISOLF是做什么的？

Isodiol International Inc., headquartered in Vancouver, Canada, is engaged in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions within Canada and the United States. The company formulates and manufactures phytoceutical consumer products, leveraging pharmaceutical and nutraceutical grade phytochemical compounds. Isodiol's product portfolio includes pharmaceutical-grade cannabinoid crystalline isolates derived from hemp, micro-encapsulations, and nanotechnology applications for consumable and topical skin care products. These technologies are used to enhance the delivery and efficacy of their products. Isodiol also manufactures and distributes hemp oil and nicotine e-liquids, catering to the evolving preferences of consumers in the wellness and lifestyle sectors. The company further extends its reach through personal care products, apparel, merchandising solutions, and hemp-infused beverages. Additionally, Isodiol supplies pharmaceutical products, aiming to serve a broad spectrum of consumer and business needs within the hemp and cannabinoid markets. The company's focus on innovation and diverse product offerings positions it to capitalize on the growing demand for hemp-derived products, while navigating the regulatory complexities of the industry.

ISOLF的投资论点是什么？

Investing in Isodiol International Inc. presents a high-risk, high-reward scenario. The company operates in the rapidly evolving hemp-based consumer packaged goods market, which offers significant growth potential. However, Isodiol's negative profit margin of -542.1% and gross margin of -24.3% indicate substantial financial challenges. The company's success hinges on its ability to achieve profitability through scaling its operations, optimizing its cost structure, and successfully launching new products. Key catalysts include expanding distribution networks and securing regulatory approvals for its pharmaceutical products. The OTC listing adds further complexity, requiring careful due diligence to assess liquidity and transparency.

ISOLF在哪个行业运营？

Isodiol International Inc. operates within the burgeoning hemp-based consumer packaged goods industry, which has experienced rapid growth due to increasing consumer acceptance of CBD and other hemp-derived products. The market is characterized by intense competition, with numerous companies vying for market share. Key trends include the development of innovative product formulations, expansion of distribution channels, and increasing regulatory scrutiny. Isodiol's focus on pharmaceutical-grade cannabinoid isolates and advanced delivery technologies positions it to potentially capture a niche within this competitive landscape, provided it can overcome its financial challenges.

Drug Manufacturers - Specialty & Generic

Healthcare

ISOLF有哪些增长机遇？

Expansion of Distribution Networks: Isodiol can grow by expanding its distribution networks across Canada and the United States. The market for hemp-based products is growing, with projections estimating the U.S. CBD market to reach billions of dollars in the coming years. Establishing partnerships with major retailers and distributors can significantly increase product visibility and accessibility, driving sales growth. Timeline: Ongoing, with continuous efforts to secure new distribution agreements.
New Product Development and Innovation: Isodiol can capitalize on the growing demand for innovative hemp-based products by investing in research and development. Developing new formulations, delivery methods, and product categories can attract new customers and increase market share. Focus on unique and differentiated products, such as pharmaceutical-grade cannabinoid isolates, can provide a competitive edge. Timeline: Ongoing, with continuous product development cycles.
Strategic Partnerships and Acquisitions: Isodiol can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with complementary businesses can create synergies and accelerate growth. Acquiring smaller companies with innovative technologies or established distribution networks can provide a competitive advantage. Timeline: Opportunistic, based on market conditions and available opportunities.
Regulatory Approvals for Pharmaceutical Products: Securing regulatory approvals for its pharmaceutical products can unlock significant growth opportunities for Isodiol. Obtaining FDA or other regulatory approvals can validate the safety and efficacy of its products, increasing consumer confidence and market acceptance. This can also open up new markets and distribution channels, such as pharmacies and healthcare providers. Timeline: Dependent on regulatory timelines and clinical trial results.
International Expansion: Isodiol can explore opportunities to expand its operations into international markets. The global market for hemp-based products is growing rapidly, with significant potential in Europe, Asia, and Latin America. Adapting its product portfolio and marketing strategies to local market conditions can drive international sales growth. Timeline: Long-term, with careful consideration of regulatory and market conditions.

Market Cap of $0.00B indicates a micro-cap company with potential for high volatility.
Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
Profit Margin of -542.1% signals significant operational inefficiencies and challenges in achieving profitability.
Gross Margin of -24.3% demonstrates that the cost of goods sold exceeds revenue, highlighting the need for cost reduction strategies.
Beta of -0.20 suggests the stock is less volatile than the market, but this may also reflect low trading volume and limited investor interest.

ISOLF提供哪些产品和服务？

Develops and markets hemp-based consumer packaged goods.
Manufactures phytoceutical consumer products.
Offers pharmaceutical-grade cannabinoid crystalline isolates.
Utilizes micro-encapsulation and nanotechnology for product delivery.
Distributes hemp oil and nicotine e-liquids.
Provides apparel and merchandising solutions.
Manufactures and sells hemp-infused beverages.
Supplies pharmaceutical products.

ISOLF如何赚钱？

Develops and manufactures hemp-based products.
Markets and distributes products through various channels.
Generates revenue through product sales.
Focuses on both consumer and pharmaceutical markets.

Consumers seeking hemp-based wellness products.
Retailers and distributors of consumer packaged goods.
Pharmaceutical companies and healthcare providers.
Individuals interested in hemp oil and nicotine e-liquids.

Proprietary formulations and manufacturing processes.
Focus on pharmaceutical-grade cannabinoid isolates.
Advanced delivery technologies like micro-encapsulation.
Established distribution networks in Canada and the United States.

什么因素可能推动ISOLF股价上涨？

Upcoming: Potential regulatory approvals for pharmaceutical products in key markets.
Ongoing: Expansion of distribution networks across Canada and the United States.
Ongoing: Development and launch of new hemp-based product formulations.
Upcoming: Strategic partnerships and acquisitions to expand market reach.
Ongoing: Increasing consumer acceptance of CBD and other hemp-derived products.

ISOLF的主要风险是什么？

Potential: Intense competition in the hemp-based products market.
Ongoing: Changing regulatory landscape and potential for stricter regulations.
Potential: Fluctuations in raw material prices and supply chain disruptions.
Potential: Negative publicity or consumer perception issues related to hemp-based products.
Ongoing: Limited financial resources and negative profit margins.

ISOLF的核心优势是什么？

Innovative product formulations and delivery methods.
Focus on pharmaceutical-grade cannabinoid isolates.
Established distribution networks in key markets.
Diverse product portfolio across consumer and pharmaceutical segments.

ISOLF的劣势是什么？

Negative profit and gross margins.
Limited financial resources.
Dependence on regulatory approvals.
OTC listing and associated risks.

ISOLF有哪些机遇？

Expansion into new geographic markets.
Development of new hemp-based products and applications.
Strategic partnerships and acquisitions.
Increasing consumer acceptance of CBD and other hemp-derived products.

ISOLF面临哪些威胁？

Intense competition in the hemp-based products market.
Changing regulatory landscape.
Fluctuations in raw material prices.
Potential negative publicity or consumer perception issues.

ISOLF的竞争对手是谁？

Arryx Therapeutics Inc — Focuses on pharmaceutical development. — (ARYX)
Attis Industries Inc — Operates in the biotechnology sector. — (ATTBF)
Bio-Path Holdings Inc — Develops RNAi therapeutics. — (BIOIF)
Cannabics Pharmaceuticals Inc — Specializes in cannabinoid-based therapies. — (CBGL)
Hemp, Inc. — Focuses on hemp-based products and solutions. — (HENC)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Marcos Agramont
Headquarters: Vancouver, CA
Founded: 2014

AI Insight

AI analysis pending for ISOLF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Isodiol International Inc. do?

Isodiol International Inc. is a company focused on developing, marketing, and distributing hemp-based consumer packaged goods and solutions, primarily in Canada and the United States. They specialize in phytoceutical consumer products, utilizing pharmaceutical and nutraceutical grade phytochemical compounds. Their offerings include cannabinoid crystalline isolates derived from hemp, micro-encapsulations, nanotechnology for skincare, hemp oil, nicotine e-liquids, apparel, hemp-infused beverages, and pharmaceutical products. Isodiol aims to capitalize on the growing market for hemp-derived products, focusing on innovation and diverse product offerings.

What do analysts say about ISOLF stock?

As of March 16, 2026, there is no readily available analyst consensus on Isodiol International Inc. (ISOLF) due to its OTC listing and limited coverage. Key valuation metrics, such as P/E ratio (-0.00) and profit margin (-542.1%), indicate significant financial challenges. Growth considerations hinge on the company's ability to achieve profitability through scaling operations, optimizing costs, and successfully launching new products. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed companies before making any investment decisions.

What are the main risks for ISOLF?

The main risks for Isodiol International Inc. (ISOLF) include intense competition in the hemp-based products market, a changing regulatory landscape, and potential fluctuations in raw material prices. The company's negative profit and gross margins also pose significant financial risks. Additionally, its OTC listing exposes investors to risks such as limited financial disclosure, low trading volume, and potential price manipulation. Investors should carefully consider these risks before investing in ISOLF.

How does Isodiol International Inc. navigate regulatory approval processes?

Isodiol International Inc. navigates regulatory approval processes by focusing on compliance with applicable laws and regulations in the jurisdictions where it operates. This includes adhering to FDA guidelines in the United States and Health Canada regulations in Canada. The company invests in quality control and testing to ensure its products meet regulatory standards. Isodiol also engages with regulatory agencies to stay informed about evolving requirements and to advocate for reasonable and science-based regulations for hemp-derived products. However, specific details on pending approvals and track record are not available.

What is Isodiol International Inc.'s drug pipeline status?

Information regarding Isodiol International Inc.'s specific drug pipeline status is not readily available. While the company supplies pharmaceutical products and develops phytoceutical consumer products, details on clinical pipeline stages, key therapeutic areas, and upcoming catalysts are not disclosed in the provided source data. Investors should seek further information from the company directly or through official press releases to assess the potential of its pharmaceutical product development efforts.